|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2100051295 |
|
最近更新日期: Date of Last Refreshed on: |
2021-09-18 12:33:08 |
|
注册时间: Date of Registration: |
2021-09-18 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
Hsp27对涎腺腺样囊性癌中EMT及VM的调节影响 |
|
Public title: |
Effects of Hsp27 on EMT and VM in adenoid cystic carcinoma of salivary gland |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
Hsp27对涎腺腺样囊性癌中EMT及VM的调节影响 |
|
Scientific title: |
Effects of Hsp27 on EMT and VM in adenoid cystic carcinoma of salivary gland |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
徐兆源 |
研究负责人: |
陈伟 |
|
Applicant: |
Yuanzhao Xu |
Study leader: |
Wei Chen |
|
申请注册联系人电话: Applicant telephone: |
18895682109 |
研究负责人电话:
Study leader's |
18602690471 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
2994358254@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
2994358254@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
天津市和平区大沽路75号天津市口腔医院 |
研究负责人通讯地址: |
天津市和平区大沽路75号天津市口腔医院 |
|
Applicant address: |
Tianjin Stomatological Hospital, 75 Dagu Road, Heping District, Tianjin |
Study leader's address: |
Tianjin Stomatological Hospital, 75 Dagu Road, Heping District, Tianjin |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
天津市口腔医院 |
||
|
Applicant's institution: |
Tianjin Stomatological Hospital |
||
|
研究负责人所在单位: |
天津市口腔医院 |
||
|
Affiliation of the Leader: |
Tianjin Stomatological Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
N/A |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
天津市口腔医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Tianjin Stomatological Hospital Medical Ethics Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2021-07-20 00:00:00 | ||
|
伦理委员会联系人: |
张淋坤 |
||
|
Contact Name of the ethic committee: |
Linkun Zhang |
||
|
伦理委员会联系地址: |
天津市和平区大沽路75号天津市口腔医院 |
||
|
Contact Address of the ethic committee: |
Tianjin Stomatological Hospital, 75 Dagu Road, Heping District, Tianjin |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
天津市口腔医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Tianjin Stomatological Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
天津市和平区大沽路75号天津市口腔医院 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Tianjin Stomatological Hospital, 75 Dagu Road, Heping District, Tianjin |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
天津市医学重点学科 |
||||||||||||||||||||||
|
Source(s) of funding: |
Tianjin key medical discipline |
||||||||||||||||||||||
|
研究疾病: |
涎腺腺样囊性癌 |
||||||||||||||||||||||
|
Target disease: |
salivary adenoid cystic carcinoma |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
病因学/相关因素研究 |
||||||||||||||||||||||
|
Study type: |
Cause/Relative factors study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
病例对照研究 |
||||||||||||||||||||||
|
Study design: |
Case-Control study |
||||||||||||||||||||||
|
研究目的: |
了解HSP27对涎腺腺样囊性癌的生物学作用 |
||||||||||||||||||||||
|
Objectives of Study: |
To understand the biological effect of HSP27 on adenoid cystic carcinoma of salivary gland |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.初治患者且均行手术治疗;2、经组织病理学检查确诊为 SACC,病理切片由两位独立的病理科医师重新评估;3、肿瘤起源于大涎腺、小涎腺。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. All the newly treated patients underwent surgical treatment; 2. SACC was confirmed by histopathological examination, and the pathological sections were re-evaluated by two independent pathologists; 3. The tumor originated from the major and minor salivary glands. |
||||||||||||||||||||||
|
排除标准: |
术前接受放疗、化疗及免疫治疗等其他治疗。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Preoperative radiotherapy, chemotherapy, immunotherapy and other treatment. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-10-01 00:00:00至 To 2021-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2021-10-01 00:00:00 至 To 2021-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
选取天津市口腔医院2012-2022年所有腺样囊性癌患者的肿瘤切片组织,根据Hsp27免疫组织化学染色结果分为阳性组和阴性组 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Tumor sections from all patients with adenoid cystic carcinoma in Tianjin Stomatological Hospital from 2012 to 2022 were selected and divided into positive group and negative group according to the immunohistochemical staining results of Hsp27 |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
- |
|
Blinding: |
- |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
试验完成后6个月内可通过咨询研究负责人邮箱获得 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Can be obtained by consulting the research person in charge within 6 months after the test is completed. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |